LBA
CBIO

Letko, Brosseau & Associates’s Crescent Biopharma CBIO Stock Holding History

Letko, Brosseau & Associates’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-453
Closed -$12.7K – 104
2024
Q2 		$12.7K Hold
453
– – ﹤0.01% 103
2024
Q1 		$136K Hold
453
– – ﹤0.01% 99
2023
Q4 		$107K Hold
453
– – ﹤0.01% 92
2023
Q3 		$67.9K Hold
453
– – ﹤0.01% 96
2023
Q2 		$78.7K Hold
453
– – ﹤0.01% 92
2023
Q1 		$57K Buy
+453
New +$102K ﹤0.01% 88

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Letko, Brosseau & Associates's CBIO Position: Q3 2024 in Review

Letko, Brosseau & Associates sold out of Crescent Biopharma (CBIO) in Q3 2024, closing a stake of 453 shares — an estimated $12.7K sold.

Letko, Brosseau & Associates first reported a position in CBIO in Q1 2023 and held it in 6 quarters. The position peaked at $136K in Q1 2024. 36 funds tracked by Wall St. Rank hold CBIO as of Q3 2024.

  • Letko, Brosseau & Associates reported no remaining Crescent Biopharma position as of Q3 2024 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 453 Crescent Biopharma shares in Q3 2024, an estimated $12.7K.
  • Letko, Brosseau & Associates first reported a position in Crescent Biopharma in Q1 2023 and held it in 6 quarters.
  • Letko, Brosseau & Associates's Crescent Biopharma position peaked at $136K in Q1 2024.
  • 36 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2024.

Based on Letko, Brosseau & Associates's 13F filing for Q3 2024, filed 7 Nov 2024.